

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Last Name:** |  | **First Name:** |  | **Middle Initial:** |  |
| **DOB:** |  | **Street Address:** |  |
| **Medical School:** |  | **City:** |  |
| **Cell Phone:** |  | **State:** |  |
| **Primary Email:** |  | **ZIP Code:** |  |
| **Student ID:** |  |  |  |

|  |  |
| --- | --- |
| **MMR (Measles, Mumps, Rubella)** *– 2 doses of MMR vaccine or two (2) doses of Measles, two (2) doses of Mumps and (1) dose of Rubella; or serologic proof of immunity for Measles, Mumps and/or Rubella. Choose only one option.* | Copy Attached |
| **Option 1** | **Vaccine** | **Date** |  |  |
| **MMR**-*2 doses of MMR**vaccine* | MMR Dose #1 |  |  |  |
| MMR Dose #2 |  |
| **Option 2** | **Vaccine or Test** | **Date** |  |  |
| **Measles***-2 doses of vaccine or positive serology* | Measles Vaccine Dose #1 |  | **Serology Results** | ☐ |
| Measles Vaccine Dose #2 |  | **Qualitative Titer Results:** |  Positive  Negative |
| Serologic Immunity (IgG antibody titer) |  | **Quantitative Titer Results:** | IU/ml |
| **Mumps***-2 doses of vaccine or positive serology* | Mumps Vaccine Dose #1 |  | **Serology Results** | ☐ |
| Mumps Vaccine Dose #2 |  | **Qualitative Titer Results:** |  Positive  Negative |
| Serologic Immunity (IgG antibody titer) |  | **Quantitative Titer Results:** | IU/ml |
| **Rubella***-1 dose of vaccine or positive serology* |  | **Serology Results** |  |
| Rubella Vaccine |  | **Qualitative Titer Results:** |  Positive  Negative | ☐ |
| Serologic Immunity (IgG antibody titer) |  | **Quantitative Titer Results:** | IU/ml |
| **Tetanus-diphtheria-pertussis** *– One (1) dose of adult Tdap. If last Tdap is more than 10 years old, provide dates of last Td and Tdap* |  |
|  | Tdap Vaccine (Adacel, Boostrix, etc) |  |  | ☐ |
| Td Vaccine *(if more than 10 years since last Tdap)* |  |
| **Varicella (Chicken Pox)** *- 2 doses of vaccine or positive serology* |  |
|  | Varicella Vaccine #1 |  | **Serology Results** | ☐ |
| Varicella Vaccine #2 |  | **Qualitative Titer Results:** |  Positive  Negative |
| Serologic Immunity (IgG antibody titer) |  | **Quantitative Titer Results:** | IU/ml |
| **Influenza Vaccine** *- 1 dose annually each fall* |  |
| *Date of last dose* |  | **Date** |  | ☐ |
| Flu Vaccine |  |
| **COVID-19 Vaccine** - *1 dose of updated (2023-2024 Formula) vaccine if previously vaccinated with any COVID-19 Vaccine.* | **Date** |  |  |
|  | Updated Pfizer-BioNTech COVID-19 vaccine |  |  | ☐ |
| Updated Moderna COVID-19 vaccine |  |  |
| Novavax COVID-19 vaccine (2 doses given 3 weeks apart if not previously vaccinated with any COVID-19Vaccine) |  |  |

|  |  |
| --- | --- |
| **Hepatitis B Vaccination** *- 3 doses of Engerix-B, PreHevbrio, Recombivax HB or Twinrix vaccines or 2 doses of Heplisav-B vaccine followed by a****QUANTITATIVE*** *Hepatitis B Surface Antibody test drawn 4-8 weeks after last vaccine dose. A test titer >10mIU/mL is positive for immunity. If the test result is negative, CDC guidance recommends that HCP receive one or more additional doses of Hepatitis B vaccine up to completion of a second series, followed by a repeat titer test 4-8 weeks after the last vaccine dose. If a single additional vaccine dose does not elicit a positive test result, administer additional vaccine doses to complete the second series using the schedule approved for the primary series of a given product. If the Hepatitis B Surface Antibody test is negative (<10 mIU/mL) after receipt of 2 complete vaccine series, a “non-responder” status is assigned. See:* [*http://dx.doi.org/10.15585/mmwr.rr6701a1*](http://dx.doi.org/10.15585/mmwr.rr6701a1) *for additional information.* | Copy Attached |
| **Primary Hepatitis B Series**Heplisav-B only requires two doses of vaccine followed byantibody testing | 3-dose vaccines (Energix-B, PreHevbrio,Recombivax HB, Twinrix) or 2-dose vaccine (Heplisav-B) | **3 Dose Series** | **2 Dose Series** |  | ☐ |
| Hepatitis B Vaccine Dose #1 |  |  |
| Hepatitis B Vaccine Dose #2 |  |  |
| Hepatitis B Vaccine Dose #3 |  |  |
| **QUANTITATIVE** Hep B Surface Antibody Test |  |  mIU/ml |
| **Additional doses of Hepatitis B Vaccine***Only If no response to**primary series*Heplisav-B only requires two doses of vaccine followed byantibody testing |  | **3 Dose Series** | **2 Dose Series** |  |  |
| Hepatitis B Vaccine Dose #4 |  |  |
| Hepatitis B Vaccine Dose #5 |  |  |
| Hepatitis B Vaccine Dose #6 |  |  |
| **QUANTITATIVE** Hep B Surface Antibody Test |  |  mIU/ml |
| **Hepatitis B Vaccine Non-responder** | If the Hepatitis B Surface Antibody test is negative (titer less than 10 mIU/mL) after a primary and repeat vaccine series, vaccine non-responders should be counseled and evaluated appropriately. Certain institutions may request signing an “acknowledgement of non-responder status” document before clinical placements. |  |
| **Additional Documentation** |  |
| ***Some institutions*** *may have additional requirements depending upon rotation, school requirements or state law. Examples include meningitis vaccine which is mandated in some states if you live in dormitory style housing. If you will be participating in an international experience, you may also be required to provide proof of vaccines such as yellow fever or typhoid.* |  |
| **Vaccination, Test or Examination** | **Date** | **Result or Interpretation** |  |
| Physical Exam (if required) |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |
|  |  |  |  |

|  |
| --- |
| **TUBERCULOSIS (TB) SCREENING –** *All U.S. healthcare personnel are screened pre-placement for TB. Two kinds of tests are used to determine if a person has been infected with TB bacteria: the TB skin test (TST) and the TB blood test (IGRA). Results of the last two TSTs or one IGRA blood test are required* ***regardless*** *of prior BCG status. If the TST method is used, record the dates and results of two 1-step annual TSTs over the last two years, or of one 2-step TST protocol (two TSTs performed with the second TST placed at least 1 week after the first TST read date). In either series, the second TST must have been placed within the past 12 months prior to clinical duties, and must have been performed in the U.S. If you have a history of a positive TST (PPD) >10mm or a positive IGR blood test, please supply information regarding any evaluation and/or treatment below. You only need to complete ONE section, A or B.****Skin test or IGRA results should not expire during proposed elective rotation dates or must be updated with the receiving institution prior to rotation.*** |
| **Tuberculosis Screening History** |
| **Please complete only one TB section based on your history** | **Section A** |  | **Date Placed** | **Date Read** | **Result** | **Interpretation** |  |
| **History of Negative TB Skin Test or Blood****Test**T-spots or QuantiFERON TB Gold blood tests for tuberculosisUse additional rows as needed | **TST #1** |  |  |  mm |  Pos  Neg  Equiv |
| **TST #2** |  |  |  mm |  Pos  Neg  Equiv |
|  |  |  |  |  |
|  |  |  |  |  |
|  | **Date** | **Result** |  |
| **QuantiFERON TB Gold or T-Spot**(Interferon Gamma Releasing Assay) |  |  Positive  Negative  Indeterminate |
| **QuantiFERON TB Gold or T-Spot**(Interferon Gamma Releasing Assay) |  |  Positive  Negative  Indeterminate |
|  |  |  |
|  |  |  |
| **Section B** |  | **Date Placed** | **Date Read** | **Result** |
| **History of Positive Skin****Test or Positive Blood****Test** | Positive TST |  |  |  mm |
|  | **Date** | **Result** |
| **QuantiFERON TB Gold or T-Spot**(Interferon Gamma Releasing Assay) |  |  Positive  Negative  Indeterminate |
| Chest X-ray\* |  | \*Provide documentation or result |
| Treated for **latent** TB infection (LTBI)? |  Yes  No |
|  |  |
|  |  |
| Date of Last Annual TB Symptom Questionnaire |  |
|  |  |  |
|  |  |  |
|  |  |
|  |  |
|  |  |



**Additional Information**

# MUST BE SIGNED BY A LICENSED HEALTHCARE PROFESSIONAL OR DESIGNEE:

|  |  |  |
| --- | --- | --- |
| **Healthcare Professional****Signature:** |  | **Date:** |
| **Printed Name:** |  | Office Use Only |
| **Title:** |  |
| **Address Line 1:** |  |
| **Address Line 2:** |  |
| **City:** |  |
| **State:** |  |
| **Zip:** |  |
| **Phone:** | **( ) - Ext:**  |
| **Fax:** | **( ) -**  |
| **Email Contact:** |  |

\*Sources:

1. [Hepatitis B In: Centers for Disease Control and Prevention. Epidemiology and Prevention of Vaccine-Preventable Diseases. Hamborsky J, Kroger A, Wolfe S, eds.](http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/hepb.pdf) [13th ed. Washington D.C. Public Health Foundation, 2015](http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/hepb.pdf)
2. [Immunization of Health-Care Personnel: Recommendations of the Advisory Committee on Immunization Practices (ACIP), MMWR, Vol 60(7):1-45](http://www.cdc.gov/mmwr/pdf/rr/rr6007.pdf)
3. [CDC Guidance for Evaluating Health-Care Personnel for Hepatitis B Virus Protection and for Administering Postexposure Management, MMWR, Vol 62(RR10):1-19](http://www.cdc.gov/mmwr/pdf/rr/rr6210.pdf)
4. [Prevention of Hepatitis B Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices, MMWR Vol 67(1):1-31](https://www.cdc.gov/mmwr/volumes/67/rr/rr6701a1.htm)
5. Sosa LE, Nijie GL, Lobato MN, et.al. Tuberculosis Screening, Testing, and Treatment of U.S. Health Care Personnel: Recommendations from National Tuberculosis Controllers Association and CDC, 2019. MMWR2019;68:439-443. https:[//w](http://www.cdc.gov/mmwr/volumes/68/wr/mm6819a3.htm?scid%2Bmm6819a3w)ww[.cdc.gov/mmwr/volumes/68/wr/mm6819a3.htm?s cid+mm6819a3 w](http://www.cdc.gov/mmwr/volumes/68/wr/mm6819a3.htm?scid%2Bmm6819a3w)